John S Sundy Selected Research

GLPG0634

2/2022	Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
2/2022	Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
1/2022	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
1/2021	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
1/2021	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
1/2021	Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.
1/2019	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John S Sundy Research Topics

Disease

20	Gout 06/2016 - 01/2006
8	Rheumatoid Arthritis 02/2022 - 01/2018
4	Infections 02/2022 - 03/2012
4	Hyperuricemia 03/2014 - 01/2006
4	Asthma (Bronchial Asthma) 03/2012 - 01/2006
2	Disease Progression 01/2020 - 03/2008
2	Opportunistic Infections (Opportunistic Infection) 01/2019 - 08/2014
2	Nasopharyngitis 01/2019 - 06/2016
2	Neoplasms (Cancer) 01/2019 - 05/2006
2	Tuberculosis (Tuberculoses) 01/2019 - 08/2014
2	Headache (Headaches) 01/2019 - 06/2016
2	Rheumatic Diseases (Rheumatism) 10/2015 - 10/2015
2	Hypersensitivity (Allergy) 01/2013 - 03/2007
2	Inflammation (Inflammations) 03/2008 - 02/2008
1	Necrosis 01/2021
1	Idiopathic Pulmonary Fibrosis 01/2020
1	Kidney Diseases (Kidney Disease) 10/2019
1	Diabetic Nephropathies (Diabetic Nephropathy) 10/2019
1	Type 2 Diabetes Mellitus (MODY) 10/2019
1	Fatigue 01/2019
1	Herpes Zoster 01/2019
1	Chronic Disease (Chronic Diseases) 01/2019
1	Retinal Vein Occlusion 01/2019
1	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2018
1	Ulcerative Colitis 08/2018
1	Crohn Disease (Crohn's Disease) 08/2018
1	Arthralgia (Joint Pain) 06/2016
1	Renal Insufficiency (Renal Failure) 06/2016
1	Injection Site Reaction 08/2014
1	Arthritis (Polyarthritis) 11/2012
1	Chronic Renal Insufficiency 03/2008
1	Ankylosing Spondylitis 05/2006
1	Fever (Fevers) 01/2006
1	Allergic Rhinitis 02/2003

Drug/Important Bio-Agent (IBA)

15	Uric Acid (Urate)IBA 06/2016 - 01/2006
11	Pegloticase FDA Link 12/2014 - 01/2006
8	Urate Oxidase (Uricase)IBA 12/2014 - 01/2006
7	GLPG0634IBA 02/2022 - 01/2019
5	Methotrexate (Mexate)FDA LinkGeneric 02/2022 - 01/2021
4	Allopurinol (Remid)FDA LinkGeneric 06/2016 - 03/2008
3	andecaliximabIBA 08/2018 - 01/2018
3	Matrix Metalloproteinase 9 (Gelatinase B)IBA 08/2018 - 01/2018
3	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 03/2014 - 09/2008
3	Febuxostat FDA Link 11/2012 - 06/2007
2	Adalimumab (Humira)FDA Link 02/2022 - 01/2021
2	Colchicine FDA LinkGeneric 06/2016 - 03/2010
2	rilonacept FDA Link 08/2014 - 03/2012
2	AntibodiesIBA 03/2014 - 03/2007
2	Interleukin-1 (Interleukin 1)IBA 03/2012 - 03/2008
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2008 - 02/2008
1	simtuzumabIBA 01/2020
1	selonsertibIBA 10/2019
1	MAP Kinase Kinase Kinase 5IBA 10/2019
1	C-Reactive ProteinIBA 01/2019
1	Antirheumatic Agents (DMARD)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 08/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Peptide Hydrolases (Proteases)FDA Link 01/2018
1	lesinuradIBA 06/2016
1	CreatinineIBA 06/2016
1	Immunoglobulin E (IgE)IBA 01/2013
1	purineIBA 11/2012
1	AntigensIBA 03/2012
1	Proteins (Proteins, Gene)FDA Link 08/2010
1	Arachidonic Acid (Vitamin F)IBA 08/2010
1	LipidsIBA 08/2010
1	AntioxidantsIBA 08/2010
1	F2-Isoprostanes (F2 Isoprostanes)IBA 08/2010
1	Clarithromycin (Biaxin)FDA LinkGeneric 03/2010
1	InflammasomesIBA 03/2008
1	Xanthine OxidaseIBA 03/2008
1	EnzymesIBA 03/2007
1	Immunoglobulin G (IgG)IBA 03/2007
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2006
1	LipopolysaccharidesIBA 01/2006
1	EndotoxinsIBA 01/2006
1	Ethylene Glycol (Monoethylene Glycol)IBA 01/2006
1	Non-Sedating Histamine H1 Antagonists (Histamine H1 Antagonists, Non Sedating)IBA 02/2003
1	Prescription DrugsIBA 02/2003
1	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2003
1	Prednisolone (Predate)FDA LinkGeneric 02/2003

Therapy/Procedure

13	Therapeutics 01/2021 - 01/2006
2	Subcutaneous Injections 08/2014 - 01/2006
2	Drug Therapy (Chemotherapy) 11/2012 - 03/2010
1	Hematopoietic Stem Cell Transplantation 10/2018